March 19, 2018 / 12:41 PM / 6 months ago

BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma

March 19 (Reuters) - Cellectar Biosciences Inc:

* CELLECTAR BIOSCIENCES GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT NEUROBLASTOMA

* ‍CELLECTAR EXPECTS TO INITIATE THIS STUDY DURING Q2 OF 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below